The White Room
Download oncology video script in PDF

Download oncology video

Add to my Selection



Size: 66.02 MB (WMV)
Rating:

Boehringer Ingelheim’s Research Facility in Vienna and Ovarian Cancer

Claudia-Nanette Gann

Interview with Claudia-Nanette Gann, MD

Oncologist, Boehringer Ingelheim
Ingelheim, Germany

 

Boehringer Ingelheim researcher Claudia-Nanette Gann gives a summary of Boehringer Ingelheim's research facility in Vienna, investigating BIBF 1120* and BIBW 2992*, and a brief overview of the unmet need in ovarian cancer.

 

*BIBW 2992 and BIBF 1120 are investigational compounds. Their safety and efficacy have not yet been fully established.

Related Documents

Items: 10
Webcast South Korea, the evolution of lung cancer care

Webcast South Korea, the evolution of lung cancer care

Targeted Therapies in Ovarian Cancer

Targeted Therapies in Ovarian Cancer

Boehringer Ingelheim and the search for new targeted cancer treatments

Boehringer Ingelheim and the search for new targeted cancer treatments

BIBF 1120 anticancer agent

BIBF 1120 anticancer agent

BIBF 1120 in ovarian cancer

BIBF 1120 in ovarian cancer

A-Z Cancer Glossary

A-Z Cancer Glossary

LUME-Ovar 1 ovarian cancer clinical trial

LUME-Ovar 1 ovarian cancer clinical trial

LUX-Lung 2 and 3 cancer clinical trial

LUX-Lung 2 and 3 cancer clinical trial

PLK1 and Polo arrest

PLK1 and Polo arrest

Clinical Trials E-Booklet Chapter 6: Summary, Checklist & Glossary

Clinical Trials E-Booklet Chapter 6: Summary, Checklist & Glossary